An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in ...
A wheelchair-bound Birmingham boy with a life limiting condition was left unable to go on holiday after a lift broke down a ...
The FDA has determined that the risk of neoplasia, including malignancy, applies to both Zolgensma and Itvisma, as they ...
When Hibaq Abdi was diagnosed with spinal muscular atrophy as a child, doctors didn't expect her to live past her teenage ...
5hon MSN
FDA probes cancer risk after tumours emerge in children treated with Novartis' SMA gene therapy
The FDA is investigating Novartis’ gene therapy Zolgensma after tumours were found in children with spinal muscular atrophy, ...
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including ...
Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.
Novartis said testing found evidence of vector DNA integration in two children who had previously received its Zolgensma gene therapy for spinal muscular atrophy. In an emailed statement to ...
Nine reports of tumors in children treated with Novartis' spinal muscular atrophy (SMA) gene therapy Zolgensma raise new ...
A multi-center study of 1312 subjects localized a common episodic memory-associated impaired network in mild cognitive ...
Muscle atrophy interventions selectively reshape mitochondrial dynamics markers, meta-analysis finds
A meta-analysis of 16 preclinical studies found that interventions for acquired muscle atrophy significantly improved grip ...
Danny Donnelly MLA said: “Every baby born in Northern Ireland should have the same opportunity for an early diagnosis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results